Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg Yothers

Showing results (81-90 of 115) with videos related to

Pageof 12
Sort By:
JNCI Cancer Spectrum|April 2, 2025
Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trialHanna Bandos, Sungjin Kim, N Lynn Henry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT GroupDaniel J Sargent, Smitha Patiyil, Greg Yothers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2012
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive valuePatrick G Gavin, Linda H Colangelo, Debora Fumagalli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2020
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant TrialsRomain Cohen, Julien Taieb, Jack Fiskum, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2024
Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national expertsJulien Taieb, Debora Basile, Jenny Seligmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2016
Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints DatabaseWinson Y Cheung, Lindsay A Renfro, David Kerr, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 18, 2020
Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance)Julia D Labadie, Xinwei Hua, Tabitha A Harrison, et al.
Frontiers in Oncology|June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trialPooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.
Breast Cancer Research and Treatment|March 22, 2023
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41Priya Rastogi, Gong Tang, Saima Hassan, et al.
Journal of the National Cancer Institute|September 10, 2021
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer TrialsJun Yin, Mohamed E Salem, Jesse G Dixon, et al.
Pageof 12

Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
JNCI Cancer Spectrum|April 2, 2025
Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trialHanna Bandos, Sungjin Kim, N Lynn Henry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT GroupDaniel J Sargent, Smitha Patiyil, Greg Yothers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2012
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive valuePatrick G Gavin, Linda H Colangelo, Debora Fumagalli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2020
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant TrialsRomain Cohen, Julien Taieb, Jack Fiskum, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2024
Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national expertsJulien Taieb, Debora Basile, Jenny Seligmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2016
Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints DatabaseWinson Y Cheung, Lindsay A Renfro, David Kerr, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 18, 2020
Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance)Julia D Labadie, Xinwei Hua, Tabitha A Harrison, et al.
Frontiers in Oncology|June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trialPooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.
Breast Cancer Research and Treatment|March 22, 2023
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41Priya Rastogi, Gong Tang, Saima Hassan, et al.
Journal of the National Cancer Institute|September 10, 2021
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer TrialsJun Yin, Mohamed E Salem, Jesse G Dixon, et al.
Pageof 12